Study to assess efficacy of a monophasic oral contraceptive preparation containing Drospirenone 3 mg/Ethinylestradiol 20 μg in the treatment of Premenstrual Dysphonic Disorder
Please see attached Study Results Summary below.
No Inclusion Criteria Available
No Exclusion Criteria Available
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation, Containing Drospirenone 3 mg/Ethinyl Estradiol 20 μg (as Beta-Cyclodextrin Clathrate), in the treatment of Premenstrual Dysphoric Disorder (PMDD)